Use of Preclinical Data for Selection of a Phase II/III Dose for Evernimicin and Identification of a Preclinical MIC BreakpointGeorge L. Drusano, William A. Craig, David R. Andes et al.|Antimicrobial Agents and Chemotherapy|2001Cited by 242